CAS Registry Number raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
=== 1964–1988: Early work and rise to prominence === Freeman worked as a dancer at the 1964 World's Fair and was a member of the Opera Ring musical theater group in San Francisco. He acted in a touring company version of The Royal Hunt of the Sun, and also appeared as an extra in Sidney Lumet's 1965 drama film The Pawnbroker starring Rod Steiger. Between acting and dancing jobs, Freeman realized that acting was where his heart lay. "After The Royal Hunt of the Sun, my acting career just took off", he later recalled. Freeman made his Off-Broadway debut in 1967, opposite Viveca Lindfors in The Niggerlovers, a show about the Freedom Riders during the American Civil Rights Movement, before debuting on Broadway in 1968's all-black version of Hello, Dolly! that also starred Pearl Bailey and Cab Calloway. In 1969, Freeman also performed on stage in The Dozens. Beginning in 1971, Freeman starred in the PBS children's television show The Electric Company, which gave him financial stability and recognition among American audiences. His work on the show was tiring, so he quit in 1975. Television producer Joan Ganz Cooney said that Freeman loathed appearing in The Electric Company, saying "it was a very unhappy period in his life". Freeman later acknowledged that he does not think about the show, but he was grateful to have been a part of it. His first credited appearance in a feature film was in 1971's Who Says I Can't Ride a Rainbow!, a family drama starring Jack Klugman. Also that year, Freeman performed in a theater production of Purlie.
The university's dental hospital moved to the Huaxiba campus in 1928 and became the Stomatological Hospital of West China Union University. During the 1930s and 1940s, the institution expanded its research and academic activities. A medical and dental research section was established in 1936, followed by a dedicated oral-disease research section in the 1940s.
Lajos Kisfaludy (30 August 1924 in Gemer, Czechoslovakia − 30 October 1988 in Budapest, Hungary) was a Hungarian chemical engineer, a corresponding member of the Hungarian Academy of Sciences. He is renowned for his research in the field of peptide synthesis and medicinal chemistry. From 1943, he studied at the Budapest University of Technology and graduated in 1948 as a chemical engineer. Until 1956, he taught at the Department of Organic Chemistry of the university. In 1956, he started to work for the Kőbánya Pharmaceutical Factory in Budapest as director and research professor of the synthesis laboratory, a position that he held from 1958 until his death. His main research was in the field of medicinal chemistry. He introduced new methods and protecting groups into the process of peptide synthesis. He contributed to the chemical synthesis of human hormones such as oxytocin and adrenocorticotropic hormone. As a result of his experiments, nearly 80 medicines were synthesized and introduced to the market (including Cavinton, Seduxen and Suprastin). He was a corresponding (1982) member of the Hungarian Academy of Sciences.
Sodium dodecyl sulfate (SDS), a common detergent, may be found in protein extracts because it is used to lyse cells by disrupting the membrane lipid bilayer and to denature proteins for SDS-PAGE. While other detergents interfere with the assay at high concentration, the interference caused by SDS is of two different modes, and each occurs at a different concentration. When SDS concentrations are below critical micelle concentration (known as CMC, 0.00333%W/V to 0.0667%) in a Coomassie dye solution, the detergent tends to bind strongly with the protein, inhibiting the protein binding sites for the dye reagent. This can cause underestimations of protein concentration in solution. When SDS concentrations are above CMC, the detergent associates strongly with the green form of the Coomassie dye, causing the equilibrium to shift, thereby producing more of the blue form. This causes an increase in the absorbance at 595 nm independent of protein presence. Other interference may come from the buffer used when preparing the protein sample. A high concentration of buffer will cause an overestimated protein concentration due to depletion of free protons from the solution by conjugate base from the buffer. This will not be a problem if a low concentration of protein (subsequently the buffer) is used. In order to measure the absorbance of a colorless compound a Bradford assay must be performed.
Sources: en.wikipedia.org
A July 2026 estimate by the group E2 found that the OBBBA had eliminated a projected 467,000 jobs for green-collar workers and caused a $68.2 billion reduction in capital investments, with grid storage batteries and solar power being the most affected industries. However, Lily Bermel of Columbia University, writing for MIT that same month, estimated that 67-74 percent of the clean energy production gains spurred by the IRA would be retained due to robust domestic demand, though the most adversely affected sector would be onshore wind.
I think that's nice because I've been lost, and I think a lot of people are lost." Ari's brother Tane Parata (Ethan Browne), their nephew Nikau Parata (Kawakawa Fox-Reo), and sister-in-law Gemma Parata (Bree Peters) were introduced in early 2020. The Paratas were the serial's first Māori family and first indigenous family to join the main cast. The actors are all New Zealand born with a Māori background. Browne revealed that the actors all auditioned together, with Kipa-Williams, Peters and Fox-Reo starting the following week, while he started a couple of months after. They established a close bond, with Kipa-Williams explaining "What's special for me is whānau, which is the Maori word for family. The cool thing about being on the show is that all of us, we didn't know each other – and I think our cultural bond bonded us to help bring what you see on screen. That gave us a sense of togetherness that came quite easily for us." Kipa-Williams said the viewers would hear different accents, humour and cultural behaviour from the family, which he thought was "nice", as every new family brings "a new vibe" to the show, but the Paratas would also bring a new culture too. Kipa-Williams, Browne and Fox-Reo wanted to include as much of the Māori culture in the show as possible, but they were unsure how much they could include. Kipa-Williams said that they started off introducing various Māori words in their dialogue, before working with the producers and scriptwriters to achieve more authenticity.
Mylodontids are the only ground sloths confirmed to have osteoderms embedded within their skin, though osteoderms were only present in a handful of genera (Mylodon, Paramylodon and Glossotherium) and absent in others.
== Stigmata and gender == In the late nineteenth century, a French physician named Dr. Antoine Imbert-Goubeyre began compiling a census of known stigmatics from the thirteenth century to his own time. This census includes 280 female and 41 male stigmatics, meaning women comprise a little over 87% of the list. Additionally, the University of Antwerp released a database of information on 244 stigmatics in April 2019. 92% of the stigmatics in the database are female. In some cases, convent sisters have attempted to shield stigmatic women from public scrutiny, often out of fear of how their condition would affect the convent's reputation. So, the number of women stigmatics may be even higher than historical record shows. Despite the high number of women stigmatics throughout history, the best-known and least contested stigmatics, such as Francis of Assisi and Padre Pio, have been men.
Amyloid beta (Aβ, Abeta or beta-amyloid) denotes peptides of 36–43 amino acids that are the main component of the amyloid plaques found in the brains of people with Alzheimer's disease. The peptides derive from the amyloid-beta precursor protein (APP), which is cleaved by beta secretase and gamma secretase to yield Aβ in a cholesterol-dependent process and substrate presentation. Both neurons and oligodendrocytes produce and release Aβ in the brain, contributing to formation of amyloid plaques. Aβ molecules can aggregate to form flexible soluble oligomers which may exist in several forms. It is now believed that certain misfolded oligomers (known as "seeds") can induce other Aβ molecules to also take the misfolded oligomeric form, leading to a chain reaction akin to a prion infection. The oligomers are toxic to nerve cells. The other protein implicated in Alzheimer's disease, tau protein, also forms such prion-like misfolded oligomers, and there is some evidence that misfolded Aβ can induce tau to misfold. A study has suggested that APP and its amyloid potential is of ancient origins, dating as far back as early deuterostomes.
Sources: en.wikipedia.org
Nickel-48, discovered in 1999, is the most neutron-poor nickel isotope known. With 28 protons and 20 neutrons 48Ni is "doubly magic" (like 208Pb) and therefore much more stable, with a half-life around 3 milliseconds, than would be expected from its position in the chart of nuclides. It has the highest ratio of protons to neutrons (proton excess) of any known doubly magic nuclide.
In 2006, the US Food and Drug Administration (FDA) approved the use of Exubera, the first inhalable insulin. It was withdrawn from the market by its maker in 2007 due to lack of acceptance. Inhaled insulin claimed to have similar efficacy to injected insulin, both in terms of controlling glucose levels and blood half-life. Currently, inhaled insulin is short-acting and is typically taken before meals; an injection of long-acting insulin at night is often still required. When people were switched from injected to inhaled insulin, no significant difference was observed in HbA1c levels over three months. Accurate dosing was a particular problem, although people showed no significant weight gain or pulmonary function decline over the length of the trial when compared to the baseline. Following its commercial launch in 2005 in the United Kingdom, it was not (as of July 2006) recommended by National Institute for Health and Clinical Excellence for routine use, except in cases where there is "proven injection phobia diagnosed by a psychiatrist or psychologist". In January 2008, the world's largest insulin manufacturer, Novo Nordisk, also announced that the company was discontinuing all further development of the company's own version of inhalable insulin, known as the AERx iDMS inhaled insulin system. Similarly, Eli Lilly and Company ended its efforts to develop its inhaled Air Insulin in March 2008.
had reported in February 2015 that Tagliavini was able to convince pro-Russian separatists during the negotiations of the Minsk II agreement because she had the benefit of Putin's trust. Saakashvili said in an interview in August 2019: "It was a politicised commission. It was quite bad because the whole idea behind the commission was to get the responsibility off Russia, to share the blame. [...] The Americans were categorically against it. [...] it was a Steinmeier game; I think backed by Merkel to dilute Russia's blame." The Atlantic Council members stated on anniversary of the war in 2021 that Russia and South Ossetia initiated the 2008 conflict and that the EU report was erroneous.
==== Poor positioning ==== Poor positioning or poor latching of infants refers to the infant's inappropriate fastening onto the mother's nipple in breastfeeding. It is the most common cause of early and persistent nipple soreness. During breastfeeding, if the infant's mouth is not in the same plane as the mother's nipple and the infant's ears, shoulders and hips are not in parallel, the child cannot grasp enough portion of the nipple and areola into the mouth nor receive enough milk. The infant will sip more vigorously and thus reduce blood flow (ischemia) at the nipple which leads to vasospasm and blanched nipples.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.